Iovance Biotherapeutics, Inc. (IOVA)
Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds
IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA's development path.
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation cell therapy platform into solid tumors the company said account for more than 100,000 US deaths a year. The clearance allows Iovance to begin clinical work on IOV-5001 and marks the platform's move beyond its current focus and into the solid tumor setting.
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.19 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out
Iovance Biotherapeutics is rated a BUY following Replimune's exit, solidifying IOVA's lead in post-PD-1 melanoma. IOVA's lifileucel shows best-in-class ORR in earlier-line melanoma and promising efficacy in NSCLC, with a strong clinical pipeline and upcoming catalysts. Commercial ramp of lifileucel is underway, with 2025 sales at $220M and gross margins improving to 50%, but operational and adoption hurdles persist.
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating despite recent share price volatility. Real-world Amtagvi data shows a 44% ORR and 73% disease control, outperforming pivotal trial results and driving increased physician adoption in less heavily pretreated patients. IOVA's pipeline catalysts include pivotal NSCLC data in 2024, sarcoma expansion with efficient trial design, and global regulatory reviews, supporting a blockbuster potential beyond melanoma.
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
Iovance Biotherapeutics (IOVA) remains a high-risk, high-reward play, with lifileucel (Amtagvi) now approved for advanced melanoma and 2025 company revenues of $264m. IOVA faces persistent losses, a precarious cash runway, and intense competition, but real-world efficacy and expanding treatment center networks support cautious optimism. Key 2026–2027 catalysts include potential approvals in NSCLC and first-line melanoma, with blockbuster ambitions hinging on successful clinical and regulatory milestones.
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit sentiment to 86 out of 100.
